6. Limitations

First, given that the report concerns a single patient, it provides only preliminary insight and a foundation for future evaluation rather than firm evidence of safety or efficacy. Second, although the 26‐month follow‐up period provides useful early clinical information, longer surveillance is still needed to evaluate late radiation toxicity, delayed wound‐healing complications, fistula recurrence, and biochemical control. Third, the patient′s RA and history of immunosuppressive therapy introduce clinical factors that may influence radiation tolerance and wound healing. Hence, results may differ in individuals with a simpler medical profile. Broader studies across multiple institutions with longer surveillance and patient populations free of major confounding conditions would offer a more authoritative basis for assessing safety, refining dose parameters, and developing consistent treatment strategies.